- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Oncology Value Coalition: Bringing Precision Medicine Solutions to the Cancer Journey, Part 5
In part 5 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed why AccessHope offers an option to payers and oncologists.
While genomic testing has changed the face of cancer care and ensure more informed decision making, designing precision medicine solutions cannot happen if patients lack access to testing, or if tests results are used incorrectly.
In the latest webinar from The American Journal of Managed Care®'s (AJMC®) Oncology Value Coalition, experts from City of Hope and Highmark highlighted the potential of genomic testing, the opportunities that exist through collaboration between academic centers and the private sector, and the barriers that some patients still face.
Joseph Alvarnas, MD, of City of Hope and editor-in-chief of AJMC®'s Evidence-Based Oncology™, moderated a discussion with:
- Afsaneh Barzi, MD, PhD, medical director, GI oncology, AccessHope; director, employer strategy, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope
- Sameera Rahman, MD, senior medical director, Highmark Inc
- Howard (Jack) West, MD, executive medical director, AccessHope; associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope
In segment 5, panelists discuss why AccessHope offers an option to payers and oncologists.
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
